Gene · 6752
Papers3,968
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,968
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Leucine Suppresses α-Cell cAMP and Glucagon Secretion via a Combination of Cell-Intrinsic and Islet Paracrine Signaling. | Diabetes | 2024 | 38870025 | PubTator, text mining | PubMed |
| Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine. | Best Pract Res Clin Endocrinol Metab | 2024 | 38845246 | PubTator, text mining | PubMed |
| Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. | J Clin Endocrinol Metab | 2024 | 38828555 | PubTator, text mining | PubMed |
| The Value of PET/CT in Particle Therapy Planning of Various Tumors with SSTR2 Receptor Expression: Comparative Interobserver Study. | Cancers (Basel) | 2024 | 38791956 | PubTator, text mining | PubMed |
| Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog. | Int J Mol Sci | 2024 | 38791582 | PubTator, text mining | PubMed |
| eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors. | EJNMMI Radiopharm Chem | 2024 | 38775990 | PubTator, text mining | PubMed |
| Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly. | JCEM Case Rep | 2024 | 38770226 | PubTator, text mining | PubMed |
| Cortistatin protects against septic cardiomyopathy by inhibiting cardiomyocyte pyroptosis through the SSTR2-AMPK-NLRP3 pathway. | Int Immunopharmacol | 2024 | 38733824 | PubTator, text mining | PubMed |
| The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells. | Int J Mol Sci | 2024 | 38612419 | PubTator, text mining | PubMed |
| Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells. | Mol Med Rep | 2024 | 38577927 | PubTator, text mining | PubMed |
| Computational studies and synthesis of 131iodine-labeled nocardiotide A analogs as a peptide-based theragnostic radiopharmaceutical ligand for cancer targeting SSTR2. | RSC Adv | 2024 | 38577429 | PubTator, text mining | PubMed |
| Predictors of biochemical response to somatostatin receptor ligands in acromegaly. | Best Pract Res Clin Endocrinol Metab | 2024 | 38575404 | PubTator, text mining | PubMed |
| Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response. | Front Immunol | 2024 | 38550578 | PubTator, text mining | PubMed |
| Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review. | Pharmaceuticals (Basel) | 2024 | 38543120 | PubTator, text mining | PubMed |
| Central hyperthyroidism due to an ectopic TSH-secreting pituitary tumor: a case report and literature review. | Front Endocrinol (Lausanne) | 2024 | 38516415 | PubTator, text mining | PubMed |
| Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors. | J Nucl Med | 2024 | 38485273 | PubTator, text mining | PubMed |
Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1. | Neuroendocrinology | 2024 | 38471465 | PubTator, text mining | PubMed |
| Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly. | J Neurooncol | 2024 | 38441839 | PubTator, text mining | PubMed |
| Identification of the metaphyseal skeletal stem cell building trabecular bone. | Sci Adv | 2024 | 38394209 | PubTator, text mining | PubMed |
| Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells. | Front Pharmacol | 2024 | 38375032 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6752/papers?page=15